Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $58M. The Maz Rating grades it against the other companies in its sector.
Insight Molecular Diagnostics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.78, Insight Molecular Diagnostics Inc. trades at 29.6x sales. Over the last twelve months it generated about $2M of revenue and a net loss of $42M. It runs a gross margin of 23.7%, an operating margin of -1795.8% and a net margin of -2137.3%. It shows return on equity of 192.1%, return on invested capital of -255.4% and a free cash flow yield of -56.8%. On the balance sheet: a debt-to-equity ratio of -0.09 and a current ratio of 1.46. Over the past 52 weeks the share price ranged from $1.63 to $7.51, with a beta of 1.86.
Insight Molecular Diagnostics Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 7 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.